ArticleJournal of endocrinological investigation2019
Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner.
Article in Journal of endocrinological investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Dynamic Changes in Circulating Endocrine FGF19 Subfamily and Fetuin-A in Response to Intralipid and Insulin Infusions in Healthy and PCOS Women.Frontiers in endocrinology · 2020Trial
- Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus.BioMed research international · 2020Trial
- Effects of Fipronil Exposure on Glucose Metabolism Disorder via the Gut Microbiota and Inflammation.Toxics · 2026Article
- Association of inflammatory cytokines with type 2 diabetes mellitus and diabetic nephropathy: a bidirectional Mendelian randomization study.Frontiers in medicine · 2024Article
- Advances in the mechanism of metformin with wide-ranging effects on regulation of the intestinal microbiota.Frontiers in microbiology · 2024Review
- Relationship between serum fibroblast growth factor 19 and vascular endothelial growth factor and soluble klotho protein in type 1 diabetic children.BMC pediatrics · 2023Article
- Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma.World journal of hepatology · 2022Article
- MECHANISMS IN ENDOCRINOLOGY: The gut-brain axis: regulating energy balance independent of food intake.European journal of endocrinology · 2021Review
- Decreased Abundance of Akkermansia muciniphila Leads to the Impairment of Insulin Secretion and Glucose Homeostasis in Lean Type 2 Diabetes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Decreased serum fibroblast growth factor 19 level is a risk factor for type 1 diabetes.Annals of translational medicine · 2021Article
- Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes.Diabetology & metabolic syndrome · 2020Article
- Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients.Diabetology & metabolic syndrome · 2019Article
- Fibroblast Growth Factor 19 (FGF-19) Expression in Glycoresistant Human Umbilical Cord Mesenchymal Stem Cells (ghUC-MSCs) and Its Regulatory Effect on Glucose Metabolism in Insulin-Resistant Hepatocytes.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeThe ileum-derived fibroblast growth factor 19 (FGF19) plays key roles in hepatic glucose homeostasis in animals in an insulin-independent manner. Here, we analyzed the association of FGF19 with glucose effectiveness (GE, the insulin-independent glucose regulation), as well as hepatic glucose production (HGP) in Chinese subjects.
methodsGE was measured by frequently sampled intravenous glucose tolerance test (FSIVGTT) in normal glucose tolerance (NGT), isolated-impaired glucose tolerance (I-IGT), and isolated-impaired fasting glucose (I-IFG) subjects. The oral glucose tolerance test-derived surrogate of GE (oGE) was determined in NGT, I-IFG, combined glucose intolerance (CGI), and type 2 diabetes (T2DM) subjects. HGP was assessed by labeled ([3-
resultsFGF19 positively correlated with GE (r = 0.29, P = 0.004) as determined by FSIVGTT. The result was further confirmed by oGE (r = 0.261, P < 0.001). FGF19 was negatively associated with FPG (r = - 0.228, P = 0.025), but the association no longer existed after adjusting for GE (r = - 0.177, P = 0.086). FGF19 was negatively associated with basal HGP (r = - 0.697, P = 0.006). However, the correlation between FGF19 and insulin secretion and sensitivity were not found.
conclusionsFGF19 levels are associated positively with GE and negatively with HGP. The increase of FPG in human is at least partially due to the decrease of FGF19 in an insulin-independent manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.